Home
  >  
Section 59
  >  
Chapter 58,588

Practical Considerations for Self-Administration of Subcutaneous Immunoglobulin G Utilizing Recombinant Human Hyaluronidase, an Advanced Method of Subcutaneous Administration: a Nurse's Perspective

Miars, L.K.; Tran, M.; Duff, K.

Journal of Infusion Nursing the Official Publication of the Infusion Nurses Society 39(6): 359-368

2016

ISSN/ISBN: 1539-0667
PMID: 27828933
DOI: 10.1097/nan.0000000000000182
Accession: 058587840
Download citation:  
Text
  |  
BibTeX
  |  
RIS
An approved subcutaneous infusion of immunoglobulin G using recombinant human hyaluronidase (IGHy) allows adult patients with primary immunodeficiency disease to self-administer every 3 to 4 weeks using 1 to 2 subcutaneous infusion site(s). This article reviews the practical considerations for nurses to simplify patient education and training. Key considerations include pump choice and parameters, ancillary supplies, and technique. Patient education includes infusion log upkeep and management of potential reactions. Educational initiatives should be designed to meet specific patient needs. Successful IGHy self-administration depends on proper patient training and continuing interaction between the health care team and the patient to optimize the patient experience.

PDF emailed within 0-6 h: $19.90




Related References

Connolly, S.; Korzemba, H.; Harb, G.; Lebel, F.; Syltevik, C. 2011: Techniques for hyaluronidase-facilitated subcutaneous fluid administration with recombinant human hyaluronidase: the increased flow utilizing subcutaneously enabled administration technique (INFUSE AT) study Journal of Infusion Nursing: the Official Publication of the Infusion Nurses Society 34(5): 300-307
Printz, M.A.; Sugarman, B.J.; Paladini, R.D.; Jorge, M.C.; Wang, Y.; Kang, D.W.; Maneval, D.C.; LaBarre, M.J. 2022: Risk Factors, Hyaluronidase Expression, and Clinical Immunogenicity of Recombinant Human Hyaluronidase PH20, an Enzyme Enabling Subcutaneous Drug Administration Aaps Journal 24(6): 110
Frost, G.I. 2007: Recombinant human hyaluronidase (rHuPH20): an enabling platform for subcutaneous drug and fluid administration Expert Opinion on Drug Delivery 4(4): 427-440
Riedl, M.A.; Lumry, W.R.; Li, H.H.; Banerji, A.; Bernstein, J.A.; Ba, M.; Bjrkander, J.; Magerl, M.; Maurer, M.; Rockich, K.; Chen, H.; Schranz, J. 2016: Subcutaneous administration of human C1 inhibitor with recombinant human hyaluronidase in patients with hereditary angioedema Allergy and Asthma Proceedings 37(6): 489-500
Locke, K.W.; Maneval, D.C.; LaBarre, M.J. 2019: ENHANZE ® drug delivery technology: a novel approach to subcutaneous administration using recombinant human hyaluronidase PH20 Drug Delivery 26(1): 98-106
Morrow, L.; Muchmore, D.B.; Ludington, E.A.; Vaughn, D.E.; Hompesch, M. 2011: Reduction in intrasubject variability in the pharmacokinetic response to insulin after subcutaneous co-administration with recombinant human hyaluronidase in healthy volunteers Diabetes Technology and Therapeutics 13(10): 1039-1045
Alonso, W.; Vandeberg, P.; Lang, J.; Yuziuk, J.; Silverstein, R.; Stokes, K.; McBride, D.; Cruz, M.; Burns, D.; Merritt, W.K.; Willis, T.; Jorquera, J.I. 2020: Immune globulin subcutaneous, human 20% solution (Xembify®), a new high concentration immunoglobulin product for subcutaneous administration Biologicals: Journal of the International Association of Biological Standardization 64: 34-40
Sandoval, M.; Coleman, P.; Govani, R.; Siddiqui, S.; Todd, K.H. 2013: Pilot study of human recombinant hyaluronidase-enhanced subcutaneous hydration and opioid administration for sickle cell disease acute pain episodes Journal of Pain and Palliative Care PharmacoTherapy 27(1): 10-18
Paassen, P.v.; Pittrow, D.; Scheidegger, C.; Klotsche, J.; Ellerbroek, P.M. 2020: Use of recombinant human hyaluronidase-facilitated subcutaneous immunoglobulin in elderly patients ImmunoTherapy 12(2): 131-139
Harb, G.; Lebel, F.; Battikha, J.; Thackara, J.W. 2010: Safety and pharmacokinetics of subcutaneous ceftriaxone administered with or without recombinant human hyaluronidase (rHuPH20) versus intravenous ceftriaxone administration in adult volunteers Current Medical Research and Opinion 26(2): 279-288
Palmer, P.A.; Atzpodien, J.; Philip, T.; Negrier, S.; Kirchner, H.; Von der Maase, H.; Geertsen, P.; Evers, P.; Loriaux, E.; Oskam, R. 1993: A comparison of 2 modes of administration of recombinant interleukin-2: continuous intravenous infusion alone versus subcutaneous administration plus interferon alpha in patients with advanced renal cell carcinoma Cancer BioTherapy 8(2): 123-136
Wasserman, R.L. 2017: Recombinant human hyaluronidase-facilitated subcutaneous immunoglobulin infusion in primary immunodeficiency diseases ImmunoTherapy 9(12): 1035-1050
Lago, M.; Pérez-García, R.; García de Vinuesa, M.S.; Anaya, F.; Valderrábano, F. 1996: Efficiency of once-weekly subcutaneous administration of recombinant human erythropoietin versus three times a week administration in hemodialysis patients Nephron 72(4): 723-724
Eguchi, K.; Shinkai, T.; Sasaki, Y.; Tamura, T.; Ohe, Y.; Nakagawa, K.; Fukuda, M.; Yamada, K.; Kojima, A.; Oshita, F. 1990: Subcutaneous administration of recombinant human granulocyte colony-stimulating factor (KRN8601) in intensive chemotherapy for patients with advanced lung cancer Japanese Journal of Cancer Research: Gann 81(11): 1168-1174
Muchmore, D.B.; Vaughn, D.E. 2012: Accelerating and improving the consistency of rapid-acting analog insulin absorption and action for both subcutaneous injection and continuous subcutaneous infusion using recombinant human hyaluronidase Journal of Diabetes Science and Technology 6(4): 764-772
Wasserman, R.L.; Melamed, I.; Stein, M.R.; Engl, W.; Sharkhawy, M.; Leibl, H.; Puck, J.; Rubinstein, A.; Kobrynski, L.; Gupta, S.; Grant, A.J.; Ratnayake, A.; Richmond, W.G.; Church, J.; Yel, L.; Gelmont, D. 2016: Long-Term Tolerability, Safety, and Efficacy of Recombinant Human Hyaluronidase-Facilitated Subcutaneous Infusion of Human Immunoglobulin for Primary Immunodeficiency Journal of Clinical Immunology 36(6): 571-582
Kang, D.W.; Jadin, L.; Nekoroski, T.; Drake, F.H.; Zepeda, M.L. 2012: Recombinant human hyaluronidase PH20 (rHuPH20) facilitates subcutaneous infusions of large volumes of immunoglobulin in a swine model Drug Delivery and Translational Research 2(4): 254-264
Shapiro, R. 2013: Subcutaneous immunoglobulin (16 or 20%) therapy in obese patients with primary immunodeficiency: a retrospective analysis of administration by infusion pump or subcutaneous rapid push Clinical and Experimental Immunology 173(2): 365-371
Loewe, L.; Rosenblatt, P. 1944: A New Practical Method for Subcutaneous Administration of Heparin American Journal of the Medical Sciences 208(1): 54-62
Roy, J. 1952: A new method for the administration of the post-pituitary ocytocic extracts during delivery slow, continuous subcutaneous infusion associated with hyaluronidase Presse Med: 1191-1192